Drug treatment for tuberculosis during pregnancy: Safety considerations

Drug Safety

Volumn 24, Issue 7, 2001, Pages 553-565

  Bothamley, G ^a  

^a HOMERTON UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; CIPROFLOXACIN; ETHAMBUTOL; ISONIAZID; LIVER ENZYME; PYRAZINAMIDE; PYRIDOXINE; RIFAMPICIN; STREPTOMYCIN; TUBERCULIN;

BCG VACCINATION; DRUG ABSORPTION; DRUG MECHANISM; DRUG SAFETY; ENZYME INDUCTION; GASTROINTESTINAL SYMPTOM; HEPATITIS; HUMAN; LIVER FUNCTION; NAUSEA; OPTIC NERVE DISEASE; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; PREGNANCY; PRIORITY JOURNAL; REVIEW; TUBERCULOSIS; VOMITING;

EID: 0034950078     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200124070-00006     Document Type: Review

References (107)

1. Global burden of tuberculosis
2. National survey of notifications of tuberculosis in England and Wales in 1983
3. Tuberculosis among immigrants to England and Wales: A national survey in 1965
4. Tuberculosis diagnosed during pregnancy: A prospective study from London
5. Prognosis of tuberculosis in married women
6. Management of pregnancy in tuberculosis patients
7. The tuberculous mother
8. Obstetrical outcomes among women with extrapulmonary tuberculosis
9. A study of maternal mortality at the University Teaching Hospital, Lusaka, Zambia: The emergence of tuberculosis as a major non-obstetric cause of maternal death
10. Care, feeding and fate of premature and full term infants born of tuberculous mothers
11. Course and outcome of pregnancy in women with pulmonary tuberculosis
12. Perinatal outcome in pregnancies complicated by pulmonary tuberculosis
13. Congenital tuberculosis: Critical reappraisal of clinical findings and diagnostic procedures
14. Relative numbers of resistant tubercle bacilli in sputa of patients before and during treatment with streptomycin
15. Global surveillance for antituberculosis-drug resistance, 1994-1997
16. Tuberculosis chemotherapy practices in major metropolitan health departments in the United States
17. The emergence of drug-resistant tuberculosis in New York City
18. Directly observed therapy and treatment adherence
19. Study on the knowledge of tuberculosis and the attitudes towards the disease
20. Illness semantics and international health: The weak lungs/FB complex in the Philippines
21. Chemotherapy and management of tuberculosis in the United Kingdom: Recommendations 1998
22. Initial therapy for tuberculosis in the era of multidrug resistance recommendations of the advisory Committee for the Elimination of Tuberculosis
23. Treatment of tuberculosis and tuberculosis infection in adults and children
24. Treating tuberculosis: What drugs, for how long?
25. Heating loss in infants of tuberculous mothers treated with streptomycin in pregnancy
26. Streptomycin and dihydrostreptomycin medication during pregnancy and their effect on the child's inner ear
27. Basic mechanisms of chemotherapy
28. Adverse reactions to daily and intermittent rifampicin regimens for pulmonary tuberculosis in Hong Kong
29. Inhibition of a Mycobacterium tuberculosis β-ketoacyl ACP synthase by isoniazid
30. The early bactericidal activity of isoniazid related to its dose size in pulmonary tuberculosis
31. Bacterial activity in vitro and in the guinea-pig of isoniazid, rifampicin and ethambutol
32. Placental transfer of isonicotinic acid hydrazide
33. The maternal and fetal effects of tuberculosis therapy
34. Nonteratogenicity of isoniazid in mice
35. Transplacental, biological and metabolic effects of isoniazid (INH) in Swiss mice
36. The search for teratogenic activity of some tuberculostatic drugs
37. A comparison of the in vitro embryotoxicity of three lathyrogens βapn semicarbazide and isoniazid Teratology
38. The inhibition of protein-lysine 6-oxidase by various lathyrogens: Evidence for two different mechanisms
39. Perinatal carcinogencitiy of isoniazid (INH) in Swiss mice
40. Tuberculosis complicated by pregnancy
41. Isoniazid therapy in relation to later occurrence of cancer in adults and infants
42. Childhood cancer and drugs in pregnancy
43. Treatment of tuberculosis in pregnancy
44. Anti-tuberculosis medication and the liver: Dangers and recommendations in management
45. Hepatitis cases in isoniazid groups and in a control group
46. Twenty isoniazid-associated deaths in one state
47. If a tree falls in the middle of the forest
48. Isoniazid hepatitis among pregnant and postpartum hispanic patients
49. Predisposing factors in hepatitis induced by isoniazid-rifampicin treatment of tuberculosis
50. The impact of anti-tuberculosis drugs upon liver function in patients with positive HBVM
51. Isoniazid related hepatitis. A U.S. Public Health Service co-operative surveillance study
52. The efficacy of various durations of isoniazid preventive therapy for tuberculosis. Five years of follow-up in the IUAT trial
53. Targeted tuberculin testing and treatment of latent tuberculosis infection
54. Hepatotoxicity of antituberculosis drugs
55. Controlled chemoprophylaxis trials in tuberculosis: A general review
56. BCG and vole bacillus vaccine in the prevention of tuberculosis in adolescence and early adult life
57. Tuberculosis in pregnancy: Interactions, diagnosis and management
58. 6 deficiency in pregnancy and some disease states
59. Mutation position and type of substitution in the β-subunit of the RNA polymerase influence in vitro activity of rifamycins in fifampicin-resistant Mycobacterium tuberculosis
60. Rifampicin in daily and intermittent treatment of experimental murine tuberculosis, with emphasis on late results
61. Observations on laboratory rodents treated with "rifamide" during pregnancy
62. Rifampicin in pregnancy
63. Rifampin, oral contraceptives and pregnancy
64. Toxic hepatitis with isoniazid and rifampicin: A meta-analysis
65. A controlled trial of 3-month, 4-month and 6-month regimens of chemotherapy for sputum-smear-negative pulmonary tuberculosis
66. The transfer of drugs and other chemicals into human milk
67. Pyrazinamide inhibits the eukaryotic-like fatty acid synthetase I (FASI) of Mycobacterium tuberculosis
68. The current status of short-course chemotherapy
69. A controlled trial of six months chemotherapy in pulmonary tuberculosis
70. Short course chemotherapy in pulmonary tuberculosis
71. Recognition of multiple effects of ethambutol on metabolism of mycobacterial cell envelopes
72. Myambutol (ethambutol hydrochloride). Commercial prospect of the drug
73. Ocular toxicity from ethambutol
74. The prevention and management of drug-resistant tuberculosis
75. Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis
76. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin
77. GyrA of oflaxacin-resistant clinical isolates of Mycobacterium tuberculosis from Hong Kong
78. Pharmokinetics of three newer quinolones in pregnant and lactating women
79. Early bactericidal and sterilizing activities of ciprofloxacin in pulmonary tuberculosis
80. The early bactericidal activity of ciprofloxacin in patients with pulmonary tuberculosis
81. Quinolone-induced arthropathy in the neonatal mouse. Morphological analysis of articular lesions produced by pipemidic acid and ciprofloxacin
82. Pregnancy outcome following gestational exposure to fluoroquinolones: A multicenter, prospective, controlled study
83. Clarithromycin is inactive against Mycobacterium tuberculosis
84. Antituberculosis activity of clarithromycin
85. Synergistic activity of clarithromycin and pyrazinamide against Mycobacterium tuberculosis in human macrophages
86. Effect of protein pump inhibitor alone or in combination with clarithromycin on mycobacterial growth in human alveolar macrophages
87. Aprospective controlled multicentre study of clarithromycin in pregnancy
88. Amoxicillin-clavulinic acid for treating drug-resistant Mycobacterium tuberculosis
89. Activity of amoxicillin/clavulanate in patients with tuberculosis
90. Prophylactic "Augmentin" in prelabor or preterm rupture of membranes
91. Congenital defects among children born to women under supervision of treatment for pulmonary tuberculosis
92. On the effect exerted by first-line tuberculosis medicines on the foetus
93. The effects of tuberculostatics on the fetus: An experimental production of congenital anomaly in rats by ethionamide
94. Effects of hydroxymethylpyrimidine on isoniazid and ethiondamide induced teratosis
95. Study of teratogenic activity of trifluroperazine, amitryptilline, ethionamide and thalidomide in pregnant rabbits and mice
96. Influence of ethionamide on development of human fetus
97. Ethionamide treatment and pregnancy
98. Inhibition of the synthesis of wax D petidoglycolipid of Mycobacterium tuberculosis by D-cycloserine
99. The tuberculin skin test
100. Lymphangitis after tuberculin tests
101. Th1-type immunity is incompatible with successful pregnancy
102. The tuberculin test in pregnancy
103. Tuberculin testing in pregnancy
104. Cutaneous anergy in pregnant and non-pregnant women with human immunodeficiency virus
105. Efficacy of BCG vaccine in the prevention of tuberculosis
106. BCG complications